Since the activity of the receptor is in part dictated by the concentration of the receptor agonists and PPARα is activated by fatty acids among others, we would expect to see higher activity of the polymorphic receptor in obesity, metabolic syndrome and type 2 diabetes (in which the levels of fatty acids are higher). The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.